Stepping Into the Race to Detect Fetal Cells in Maternal Blood
Many companies have tried and failed to develop tools that could detect fetal cells in maternal blood. Their aim would be to detect pre-natal abnormalities more accurately and earlier than existing tests and to replace invasive methods, such as amniocentesis. Roche Diagnostics started a program in this field six years ago and found several markers distinguishing fetal from maternal cells in blood. But its priorities shifted and recently it licensed the technology to Vysis, which has been doing chromosomal analysis of fetal cells gleaned from amniocentesis
You may also be interested in...
Tiny Vysis scored big this spring, winning the backing of two major therapeutic and diagnostic companies for its products. But is its core technology ready for prime time? Vysis sees an opportunity to expand use of its FISH diagnostics technology beyond niche applications in the clinical market. But skeptics say the technology is too complex and expensive for routine clinical use.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.